Understanding how PD-1 signaling affects T cells in cancer treatment
Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy
This study is looking at how a protein called PD-1 affects T cells, which are important for fighting cancer, and it aims to find ways to boost these cells' ability to work better against tumors in cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11003708 on NIH RePORTER |
What this research studies
This research investigates the role of PD-1 signaling in T cells and how it impacts their ability to fight cancer. By examining the interactions between PD-1 and its ligands in both tumor environments and healthy individuals, the study aims to uncover the mechanisms that inhibit T cell activation. The researchers have developed a specific antibody to detect a phosphorylated form of PD-1, which is crucial for understanding its inhibitory effects. This work could lead to improved strategies for enhancing anti-tumor immunity in cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are currently treated with PD-1 blocking agents.
Not a fit: Patients with cancers that do not involve PD-1 signaling or those who are not candidates for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that enhance the body's ability to fight tumors.
How similar studies have performed: Previous research has shown promising results with PD-1 blockade in cancer treatment, indicating that this approach has potential for significant advancements.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Boussiotis, Vassiliki a — Beth Israel Deaconess Medical Center
- Study coordinator: Boussiotis, Vassiliki a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.